Citi analyst Patrick Donnelly lowered the firm’s price target on Labcorp to $235 from $260 and keeps a Neutral rating on the shares. The analyst reduced estimates post the Q1 report to reflect softening Drug Discovery results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on LH: